[Postcovid cognitive impairment].
V N ShishkovaB G DranitsinaPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2022)
This review addresses current issues in post-COVID syndrome with a focus on neurocognitive impairment. The results of studies on complications in patients of different ages and health statuses recovered from mild to severe COVID-19 are discussed. Current data on the pathogenetic mechanisms of the development of various post-COVID disorders are presented, including a detailed discussion of central nervous system damage. The paper summarizes data on the relationship between neurocognitive disorders and accelerated cell aging, chronic nonspecific inflammation, and reduced neuroplasticity in the central nervous system. The main pathogenetic ways to prevent COVID-related complications, including neuronal tissue damage and the prospects for managing such patients are discussed. The choice of pathogenetic therapy in patients with neurocognitive impairment in the post-COVID period is assessed. The main benefits of choline alfoscerate therapy for neurocognitive impairment in patients with post-COVID syndrome are discussed.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- chronic kidney disease
- oxidative stress
- ejection fraction
- bipolar disorder
- respiratory syndrome coronavirus
- healthcare
- peritoneal dialysis
- prognostic factors
- public health
- stem cells
- risk factors
- electronic health record
- risk assessment
- climate change
- patient reported outcomes
- mesenchymal stem cells
- early onset
- cell therapy
- case report
- subarachnoid hemorrhage
- artificial intelligence